Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 26, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 26, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/26/18 - Adapt Pharma and Kaleo Donate Life-Saving Naloxone to the National Council for Behavioral Health
In response to the Surgeon General's call to make naloxone widely available it was announced today at NatCon18, the annual conference of National Council for Behavioral Health, that pharmaceutical companies, Adapt Pharma and Kaleo, are donating doses of naloxone, a potentially lifesaving drug that can help reverse opioid overdoses, to the National
4/26/18 - Aluminum Adjuvanted Recombinant Vaccine Drug Product (DP) Formulation Evaluation, DP Process Development and Clinical/Commercial DP Formulation and Filling.
Office Address: Department of the Army; Army Contracting Command; ACC- APG Natick; 10 General Green AvenueBuilding 1 Natick MA 01760-5011. Description: Department of the Army. DynPort Vaccine Company LLC, a General Dynamics Information Technology Company, a biopharmaceutical company in Frederick, Maryland, is issuing this Request for Information to
4/26/18 - Compounded Pharmaceuticals
Office Address: Department of the Army; U.S. Army Medical Command; REGIONAL HEALTH CONTRACT OFF CENTRAL; ATTN: MCAA GP L31 9 V2539 GARDEN AVENUE JBSA FT SAM HOUSTON TX 78234-0000. Contact: Timothy T. Hoerz, Phone 2542856747, Email Description: Department of the Army.
4/26/18 - Digestible Medical Sensors Market Highly Favorable to the Growth Rate by 2022: The globaldigestible medical sensors market is expected to witness a favorable growth during the forecast period.
Albany, NY 04/25/2018 Digestible Medical Sensor helps the doctor/caregiver get patient data on mobile application. Digestible Medical senor will be used for medical adherence and study vital signs. Digestible medical Sensor is a new technology in the market with recent FDA approval to market in United States and Europe.
4/26/18 - EYPT Up 98% This Month, USNA In Good Health, MDXG To Report Q1 Results
On March 28, 2018, pSivida Corp. acquired specialty biopharmaceutical company Icon Bioscience Inc. pSivida Corp. rebranded and changed its name to EyePoint Pharmaceuticals Inc., with ticker EYPT, effective April 2, 2018. DEXYCU, a dropless, long-acting therapeutic, which was approved by the FDA for the treatment of inflammation in post catara
4/26/18 - Further MP0250 Clinical Data and Partner Interest Underline Molecular Partners' Continued Progress of Its Proprietary Oncology Compounds
Bill Burns elected Chairman of Molecular Partners at the 2018 AGM on April 18 Talent base with 113 full-time employees, reflecting further build-out of oncology expertise. ZURICH- SCHLIEREN, SWITZERLAND/ ACCESSWIRE/ April 26, 2018/ Molecular Partners AG, a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin t
4/26/18 - GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that five abstracts were accepted at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting in Honolulu, Hawaii, April 29 May 3,
4/26/18 - Global Drug Rescue Market Is Driven by Prevalence of Allergic Conditions Rises: Drug Rescue Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Albany, NY 04/25/2018 Drug rescue is also termed as rescue medicines. These are given only when needed or in emergency cases. Drug which is given to counter or block the effect of other medicines are called as rescue medicines.
4/26/18 - Immunology Biosimilars Market to Make Great Impact in Near Future by 2025: Transparency Market Research Report Added "Immunology Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025"
Albany, NY 04/26/2018 A biosimilar medicine possesses similar pharmacokinetic and mode of action as an original biological medicine that has already been approved for therapeutic use. Biosimilars are made from a living organism such as bacteria and yeast or can also be derived from small molecules such as human insulin, erythropoietin, and mo
4/26/18 - Moberg Pharma's report for the first quarter to be published on May 8 - Invitation to teleconference
STOCKHOLM, April 26st, 2018- On May 8th 2018, at 08:00 am, Moberg Pharma AB will present its interim report for January- March 2018. The teleconference will be hosted by Moberg Pharmas's CEO Peter Wolpert and CFO Anna Ljung. About Moberg Pharma, Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales
4/26/18 - Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
By a News Reporter-Staff News Editor at Gene Therapy Weekly Pfizer Inc. has initiated a Phase 1 b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy. "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfiz
4/26/18 - Rep. Matsui Issues Opening Remarks at Health Subcommittee Markup of Opioid Legislation
Doris O. Matsui, D- California, issued the following opening remarks at the House Energy and Commerce subcommittee on Health markup on opioid legislation and the Animal Drug and Animal Generic Drug User Fee Amendments:. "Our Committee has a daunting, yet absolutely essential, task before us today: to make policy changes that address the opioid epi
4/26/18 - Rising Number of Chronic Diseases Is Expected to Fuel Demand for Single-Dose Container Market: Single-dose Container Market rising rapidly as progression in viruses has been witnessed, leading to increasing new diseases and viral infections
Albany, NY 04/25/2018 The packaging industry is witnessing an impressive growth over the past few years and various new packaging solutions are launched in order to cater increasing need of customers. Packaging of medicines is a complicated process, due to its complex molecular structure of chemicals used in origination of drugs. So, there is
4/26/18 - Saniona progress to second part of Phase 2a study for Tesomet in Prader-Willi Syndrome based on positive results in adult patients
Saniona, a leading biotech company in the field of ion channels, today announced that it has obtained approval to initiate the second part of its Phase 2 a trial for Tesomet in adolescents with Prader-Willi syndrome. By pursuing an orphan indication such as Prader-Willi syndrome, we may develop and commercialize our own product in the U.S. and Euro
4/26/18 - Vitamin Deficiency Treatment Market to Hold a High Potential for Growth by 2022: North America will continue to hold largest share in the global vitamin deficiency treatment market due to increasing health consciousness.
Albany, NY 04/25/2018 Vitamin deficiency, also called as hypovitaminosis, is primarily caused by malnutrition. The rate of undernourishment is high in undeveloped and developing countries such as Africa, Vienna and some parts of South-East Asia. Vitamin deficiency can lead to various diseases such as vitamin D deficiency causes rickets, vitam
4/26/18 - Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome. Glepaglutide is in development as a new treatment option for patients with short bowel syndrome The pivotal phase 3 trial is on track for initiation in Q3 2018 Copenhagen, Denmark, April 26, 2018- Zealand Pharma today announced receipt of the End-
4/25/18 - 22nd Century Committed to Advancing FDA's Nicotine Mandate
22nd Century Group, Inc., a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company is committed to working collaboratively with the U.S. Food and Drug Administration on the FDA s planned nicotine reduction mandate despite the fact that, last week, published re
4/25/18 - Acasti Pharma Prices $10 Million Underwritten Offering [Sudan Tribune]
-Acasti Pharma Inc. is pleased to announce that, in connection with its overnight marketed public offering previously announced on April 23, 2018, it has entered into an underwriting agreement with Mackie Research Capital Corporation to sell 9,530,000 units of the Company at a price of CDN $1.05 per Unit, with each such Unit comprising one common s
4/25/18 - AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 9th, 2018. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time on May 9th, 2018 to discuss the financial results and provide a corpora
4/25/18 - Acetylon Pharmaceuticals Assigned Patent for Combinations of Histone Deacetylase Inhibitors
Acetylon Pharmaceuticals, Boston, Massachusetts, has been assigned a patent developed by two co-inventors for "combinations of histone deacetylase inhibitors and immunomodulatory drugs." The co-inventors are Steven Norman Quayle, Brookline, Massachusetts, and Simon Stewart Jones, Harvard, Massachusetts. Written by Sudarshan Harpal; edited by Sudars
4/25/18 - ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors
LAUSANNE, Switzerland ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates targeting major cancers, today announced that it has terminated the Phase I clinical trial to evaluate its antibody drug conjugate ADCT-502 in patients with advanced solid tumors
4/25/18 - ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership [Arab News (Saudi Arabia)]
-ADMA Biologics, Inc., today announced that it has successfully completed the manufacturing, release and has made commercial sales of its first batch of Nabi-HB, produced under its leadership. ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for t
4/25/18 - Adult Diapers May No Longer Be Needed Thanks To Amazing New Pill
AHP- Adult diaper sales are expected to plummet as results from a clinical trial on a new, patented bladder control pill have finally been released. Sold under the brand name UriVarx?, the new pill contains key ingredients that keeps the bladder from releasing voluntarily, which reduces accidents and fretiuent bathroom trips. Bassam Damaj of Inno
4/25/18 - Ajay Singh of Slayback Pharma named Ernst and Young's Entrepreneur Of The Year 2018 Award Finalist in New Jersey
Slayback Pharma today announced that CEO, Ajay Singh of Slayback Pharma LLC is named as one of the finalists for Ernst and Young's Entrepreneur Of The Year 2018 Award in the New Jersey region. Ajay Singh was selected as a finalist by a panel of independent judges. In the New Jersey, regional sponsor include PNC Bank, DLA Piper, Morgan Lewis, P
4/25/18 - Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine [T-break Tech (Middle East)]
Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. Detailed results will be presented today at the 70th Annual American Academy of Neurology Meeting
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement